A surge in private market investment has Fools wondering: is it time to bet bigger on biotech?
Tim Beyers and Karl Thiel discuss:
- The rise in biotech funding from VCs and wealthy individuals.
- The key attributes of an investable biotech.
- Which is the better biotech: Viking Therapeutics or Eli Lilly?
Companies discussed: VKTX, LLY, MRK
Host: Tim Beyers and Karl Thiel
Producer: Anand Chokkavelu
Engineer: Dan Boyd, Natasha Hall
Disclosure: Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Learn more about your ad choices. Visit megaphone.fm/adchoices